The Asia Pacific Hemoglobinopathies Market would witness market growth of 6.1% CAGR during the forecast period (2022-2028).
With the help of penicillin prophylaxis, SCD can be detected early, which drops downs the risk of Streptococcus pneumoniae (pneumococcus) infection. Additionally, if SCD is detected early, healthcare workers can educate the family about the disease and give preventive advice to provide total care to the patient. Other hemoglobinopathies seen through newborn screening are classified as secondary targets; HbE, HbSE, and HbC disease are some examples.
Newborn screening and diagnosis may differ in different laboratory programs. While some of them detect only common variants, others might identify multiple variants. While some techniques are manual and labor-intensive, others are automated. For diagnostics methods that include applications based on DNA, some procedures require highly specialized equipment.
Some Programs also have different structures. Though some laboratories only screen, others perform both diagnostic testing and screening. Before referring the patients for diagnostic testing, in some cases, a second-tier evaluation is recommended to confirm an abnormal result. Also, different programs will have additional reporting and follow-up algorithms.
Hemoglobinopathy causes a serious burden on the health care system and the families as being a primary cause of morbidity and mortality in India. There are about 1 to 1.5 lakhs Thalassemia major patients, which is the highest in the world, and about 42 million carriers of the beta thalassemia trait. Around 10,000 to 15,000 children are born annually with thalassemia major. Many regions in India are affected by sickle cell disease, like central India, Maharashtra, and Kerala.
The China market dominated the Asia Pacific Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $506.5 Million by 2028. The Japan market is registering a CAGR of 5.5% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 6.8% during (2022 - 2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Hemoglobinopathies Market is Projected to reach USD 6 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
By Type
By Distribution Channel
By Therapy
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
